Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Retained Earnings (2016 - 2026)

Ocular Therapeutix has reported Retained Earnings over the past 14 years, most recently at -$1.2 billion for Q1 2026.

  • For Q1 2026, Retained Earnings fell 30.41% year-over-year to -$1.2 billion; the TTM value through Mar 2026 reached -$1.2 billion, down 30.41%, while the annual FY2025 figure was -$1.2 billion, 29.84% down from the prior year.
  • Retained Earnings for Q1 2026 was -$1.2 billion at Ocular Therapeutix, down from -$1.2 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at -$558.3 million in Q1 2022 and troughed at -$1.2 billion in Q1 2026.
  • A 5-year average of -$812.4 million and a median of -$762.4 million in 2024 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: decreased 4.14% in 2022 and later tumbled 30.41% in 2026.
  • Year by year, Retained Earnings stood at -$616.8 million in 2022, then fell by 13.09% to -$697.6 million in 2023, then fell by 27.74% to -$891.1 million in 2024, then dropped by 29.84% to -$1.2 billion in 2025, then dropped by 7.66% to -$1.2 billion in 2026.
  • Business Quant data shows Retained Earnings for OCUL at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.